Novelix Pharma Q1 FY27 Results: Revenue Grows 65% to Rs 36 Crore, PAT Surges to Rs 1 Crore
- August 17, 2026
- Posted by: Kunal Singla
- Category: Market
Novelix Pharma Q1 FY27: Revenue Rs 36 Cr (+65.15% YoY). PAT Rs 1 Cr (+1001.78%). Gross profit Rs 1 Cr vs Rs 0.17 Cr (+625.8%). Standalone. CMP Rs 73.97 on Aug 13, 2026.
Quick Answer
Novelix Pharma Q1 FY27 results showed standalone revenue growing 65% to Rs 36 crore and PAT surging approximately 1002% to Rs 1 crore as the pharmaceutical company crossed manufacturing scale breakeven thresholds.
Novelix Pharma Q1 FY27 results showed the pharmaceutical formulations company posting 65.15% revenue growth to Rs 36 crore from Rs 22 crore in Q1 FY26, reflecting new product launches, expanded distribution, or institutional pharma market entry.
The Novelix Pharma Q1 FY27 results showed gross profit jumping 625% from Rs 0.17 crore to Rs 1 crore on 65% revenue growth — a scale economy crossover where higher API procurement volumes and better capacity utilisation dramatically reduced per-unit manufacturing costs.
Click Here – Get Free Investment Predictions
Novelix Pharma Q1 FY27 Financial Highlights
| Metric | Q1 FY27 (Rs Crore) | Q1 FY26 (Rs Crore) | YoY Change |
|---|---|---|---|
| Revenue | 36.00 | 22.00 | +65.15% |
| Gross Profit | 1.00 | 0.17 | +625.8% |
| Net Profit / PAT | 1.00 | 0.11 | +1001.78% |
Novelix Pharma Q1 FY27 Performance Analysis
Use the Univest Screener to track Novelix Pharma live financials and Q1 FY27 results
Novelix Pharma Q1 FY27 results demonstrate pharmaceutical operating leverage. Revenue crossing a scale threshold reduces per-unit API and manufacturing costs, driving the disproportionate 625% gross profit improvement on 65% revenue growth.
PAT surging 1002% from Rs 0.11 crore to Rs 1 crore confirms the company is now meaningfully above its profitability breakeven point in pharmaceutical manufacturing.
At Rs 36 crore quarterly revenue and Rs 1 crore PAT (2.8% margin), Novelix Pharma has significant headroom for margin improvement as revenue scales further — pharma manufacturing margins typically improve substantially at higher volumes.
India’s growing generic pharmaceutical market and government healthcare spending expansion provide structural demand tailwinds for formulations companies like Novelix Pharma.
Key Business Factors in Q1 FY27
Pharmaceutical Scale Economies
Higher API procurement volumes and better capacity utilisation drove the 625% gross profit improvement on 65% revenue.
Generic Pharma Growth
India’s domestic and export generic pharma demand drives Novelix Pharma’s revenue growth trajectory.
Operating Leverage
PAT surging 1002% on 65% revenue growth reflects pharmaceutical operating leverage above the breakeven threshold.
Dividend Details
Novelix Pharma has not declared a dividend for Q1 FY27. The company is reinvesting in product development and distribution expansion.
FY27 Outlook
The FY27 outlook is positive. Continued revenue growth with improving pharmaceutical manufacturing margins would significantly increase PAT from the Q1 FY27 results base.
Regulatory approvals, API cost management, and competition from larger pharma companies are the key risk factors.
Novelix Pharma Stock Performance
Download the Univest iOS App or Univest Android App to track Novelix Pharma share price live and stay updated on quarterly results.
Novelix Pharma shares traded at Rs 73.97 on August 13, 2026, up 1.34%, reflecting positive market reception of the Q1 FY27 results growth trajectory.
Key Risks
Regulatory Risk
New product launches require regulatory approvals. Delays would slow revenue growth.
API Price Volatility
Active pharmaceutical ingredient costs are subject to global supply fluctuations from key sourcing markets.
Competition from Larger Pharma
Generic formulations markets are competitive. Larger companies have scale and distribution advantages.
Conclusion
Novelix Pharma Q1 FY27 results show impressive 65% revenue growth to Rs 36 crore and PAT surging 1002% to Rs 1 crore as pharmaceutical scale economies kicked in.
Strong growth trajectory but investors should assess product pipeline and competitive positioning. Consult a SEBI-registered advisor.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Novelix Pharma Q1 FY27 Results
When were Novelix Pharma Q1 FY27 results announced?
Ans. August 13, 2026, standalone basis.
What was Novelix Pharma revenue in Q1 FY27?
Ans. Rs 36 crore, up 65.15% from Rs 22 crore.
What was Novelix Pharma PAT in Q1 FY27?
Ans. Rs 1 crore, up approximately 1002% from Rs 0.11 crore.
Why did PAT surge 1002% on 65% revenue growth?
Ans. Scale economies in pharmaceutical manufacturing dramatically reduce per-unit API and production costs at higher volumes, crossing the profitability breakeven threshold.
Did Novelix Pharma declare a dividend?
Ans. No dividend for Q1 FY27.
What is the outlook?
Ans. Positive with continued revenue growth. Monitor regulatory pipeline and competition.
Is Novelix Pharma a good investment?
Ans. Strong growth story. Assess product portfolio and regulatory status. Consult a SEBI-registered advisor.
